Pliant Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Pliant Therapeutics, a clinical stage biotechnology company, announced its participation in two upcoming investor conferences. The Citi 16th Annual BioPharma Virtual Conference is set for September 8-9, 2021, where the management team will engage in one-on-one meetings. Following this, the Cantor 2021 Virtual Global Healthcare Conference will occur on September 29, 2021, featuring a presentation by CEO Bernard Coulie at 2:40 p.m. ET, along with additional one-on-one meetings. Pliant is focused on developing therapies for fibrosis, including its lead candidate for idiopathic pulmonary fibrosis and primary sclerosing cholangitis.

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced participation in the following investor conferences:

• Citi 16th Annual BioPharma Virtual Conference – Pliant’s senior management team will participate in one-on-one meetings with members of the investment community September 8 - 9, 2021
• Cantor 2021 Virtual Global Healthcare Conference – Bernard Coulie, M.D., Ph.D., Pliant’s President and Chief Executive Officer, will present on Wednesday, September 29, 2021, at 2:40 p.m. ET / 11:40 a.m. PT and, along with members of Pliant’s senior management team, will participate in one-on-one meetings with members of the investment community

The webcast replay of the Cantor conference presentation will be archived for 90 days following the conclusion of the event.

About Pliant Therapeutics, Inc.

Pliant is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting Phase 2a trials of PLN-74809 in the lead indications of IPF and PSC. Pliant has also developed PLN-1474, a small-molecule selective inhibitor of αvß1 for the treatment of nonalcoholic steatohepatitis, or NASH with liver fibrosis, which Pliant has transferred to Novartis pursuant to its development partnership. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies. For additional information about Pliant, visit www.pliantrx.com and follow us on Twitter, LinkedIn, Facebook, and YouTube.

Investor and Media Contact:

Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com

 

FAQ

When is Pliant Therapeutics participating in the Citi 16th Annual BioPharma Virtual Conference?

Pliant Therapeutics will participate in the Citi 16th Annual BioPharma Virtual Conference on September 8-9, 2021.

Who will represent Pliant Therapeutics at the Cantor 2021 Virtual Global Healthcare Conference?

CEO Bernard Coulie will present on September 29, 2021, at 2:40 p.m. ET during the Cantor 2021 Virtual Global Healthcare Conference.

What is the main focus of Pliant Therapeutics?

Pliant Therapeutics focuses on discovering and developing therapies for fibrosis.

What is PLN-74809 and its significance for Pliant Therapeutics?

PLN-74809 is Pliant's lead product candidate, targeting idiopathic pulmonary fibrosis and primary sclerosing cholangitis, and has received Orphan Drug Designation.

How long will the webcast replay of the Cantor conference presentation be available?

The webcast replay of the Cantor conference presentation will be archived for 90 days after the event.